Kala Pharmaceuticals (KALA) financial statements
Kala Pharmaceuticals reported revenue of $0 in fiscal 2025, down 13.8% a year over 3 years.
Net income was -$27M.
Free cash flow was -$32M.
The diluted share count rose 34385% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Kala Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | $6M | $6M | $11M | $4M | $0 | $0 | $0 |
| Research and development | $25M | $29M | $29M | $27M | $18M | $12M | $18M | $19M | $22M | $19M |
| Selling, general and admin | $8M | $11M | $35M | $65M | $81M | $105M | $65M | $21M | $18M | $24M |
| Operating income | -$33M | -$40M | -$65M | -$88M | -$96M | -$130M | -$82M | -$40M | -$41M | -$39M |
| Interest expense | $767,000 | $1M | $3M | $8M | $9M | $8M | $7M | $6M | $6M | $3M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$33M | -$42M | -$67M | -$94M | -$104M | -$143M | -$45M | -$42M | -$39M | -$27M |
| EPS (diluted) | -$70,175.00 | -$9,275.00 | -$6,225.00 | -$6,900.00 | -$4,975.00 | -$5,416.00 | -$1,474.00 | -$867.50 | -$507.50 | -$165.50 |
| Diluted shares | 0M | 0M | 0M | 0M | 0M | 0M | 0M | 0M | 0M | 0M |
| Operating margin | — | — | — | -1452.5% | -1512.6% | -1158.8% | -2099.3% | — | — | — |
| Net margin | — | — | — | -1553.3% | -1639.8% | -1268.7% | -1151.6% | — | — | — |
Balance sheet
Fiscal years, from Kala Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $45M | $115M | $171M | $85M | $154M | $92M | $70M | $51M | $51M | $8M |
| Receivables | — | — | — | $12M | $10M | $15M | $195,000 | — | — | — |
| Inventory | — | — | $4M | $5M | $5M | $9M | — | — | — | — |
| Total current assets | $46M | $115M | $177M | $105M | $171M | $124M | $86M | $53M | $53M | $9M |
| Property, plant and equipment | $594,000 | $786,000 | $2M | $3M | $3M | $3M | $400,000 | $753,000 | $749,000 | — |
| Total assets | $46M | $117M | $221M | $154M | $222M | $139M | $87M | $56M | $55M | $9M |
| Total current liabilities | $6M | $15M | $17M | $25M | $22M | $37M | $26M | $8M | $17M | $2M |
| Long-term debt | $9M | $12M | $70M | $71M | $72M | $79M | $38M | $34M | $20M | — |
| Total liabilities | $16M | $27M | $116M | $125M | $122M | $123M | $68M | $48M | $43M | $2M |
| Shareholders' equity | -$88M | $90M | $105M | $30M | $100M | $17M | $19M | $8M | $12M | $7M |
| Net debt | -$36M | -$96M | -$101M | -$14M | -$5M | -$13M | -$28M | -$17M | -$21M | -$8M |
Cash flow
Fiscal years, from Kala Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$27M | -$34M | -$54M | -$93M | -$91M | -$108M | -$79M | -$28M | -$29M | -$32M |
| Capital spending | $153,000 | $480,000 | $2M | $1M | $130,000 | $139,000 | $9,000 | $610,000 | $208,000 | $15,000 |
| Free cash flow | -$28M | -$35M | -$56M | -$94M | -$91M | -$108M | -$79M | -$29M | -$30M | -$32M |
| Stock-based compensation | $2M | $4M | $9M | $10M | $13M | $16M | $7M | $7M | $8M | $7M |
| Net borrowing | $1M | $10M | $72M | — | — | $78M | — | — | — | — |
| Free cash flow margin | — | — | — | -1548.5% | -1427.6% | -964.2% | -2027.7% | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for KALA.
Open KALA in InvestinglyQuestions
What was Kala Pharmaceuticals's revenue in 2025?
$0 in fiscal 2025, from its 10-K filing.
How much free cash flow does Kala Pharmaceuticals generate?
-$32M in fiscal 2025 (operating cash flow minus capital spending).
From Kala Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.